149 related articles for article (PubMed ID: 14508834)
1. Cyclooxygenase-2 in oligodendroglial neoplasms.
Castilla EA; Prayson RA; Kanner AA; Rybicki LA; Tubbs RR; Vogelbaum MA; Barnett GH
Cancer; 2003 Oct; 98(7):1465-72. PubMed ID: 14508834
[TBL] [Abstract][Full Text] [Related]
2. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
[TBL] [Abstract][Full Text] [Related]
3. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas.
Prayson RA; Mohan DS; Song P; Suh JH
Ann Diagn Pathol; 2000 Aug; 4(4):218-27. PubMed ID: 10982299
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived growth factor expression correlates with tumor grade and proliferative activity in human oligodendrogliomas.
Majumdar K; Radotra BD; Vasishta RK; Pathak A
Surg Neurol; 2009 Jul; 72(1):54-60. PubMed ID: 19559929
[TBL] [Abstract][Full Text] [Related]
6. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
Ali-Fehmi R; Che M; Khalifeh I; Malone JM; Morris R; Lawrence WD; Munkarah AR
Cancer; 2003 Oct; 98(7):1423-9. PubMed ID: 14508829
[TBL] [Abstract][Full Text] [Related]
7. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
8. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 1p allelic loss by fluorescence in situ hybridization is not observed in dysembryoplastic neuroepithelial tumors.
Prayson RA; Castilla EA; Hartke M; Pettay J; Tubbs RR; Barnett GH
Am J Clin Pathol; 2002 Oct; 118(4):512-7. PubMed ID: 12375636
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.
Shono T; Tofilon PJ; Bruner JM; Owolabi O; Lang FF
Cancer Res; 2001 Jun; 61(11):4375-81. PubMed ID: 11389063
[TBL] [Abstract][Full Text] [Related]
11. Expression of hypoxia-related tissue factors correlates with diminished survival of adjuvantly treated patients with chromosome 1p aberrant oligodendroglial neoplasms and therapeutic implications.
Birner P; Preusser M; Gelpi E; Berger J; Gatterbauer B; Ambros IM; Ambros PF; Acker T; Plate KH; Harris AL; Hainfellner JA
Clin Cancer Res; 2004 Oct; 10(19):6567-71. PubMed ID: 15475445
[TBL] [Abstract][Full Text] [Related]
12. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
13. Co-expression of Cox-2 and EGFR in stage I human bronchial adenocarcinomas.
Araki K; Hashimoto K; Ardyanto TD; Osaki M; Shomori K; Nakamura H; Ito H
Lung Cancer; 2004 Aug; 45(2):161-9. PubMed ID: 15246187
[TBL] [Abstract][Full Text] [Related]
14. The expression of cell cycle regulatory proteins in oligodendroglial tumors.
Kamiya M; Nakazato Y
Clin Neuropathol; 2002; 21(2):52-65. PubMed ID: 12005253
[TBL] [Abstract][Full Text] [Related]
15. Survival analysis of presumptive prognostic markers among oligodendrogliomas.
McLendon RE; Herndon JE; West B; Reardon D; Wiltshire R; Rasheed BK; Quinn J; Friedman HS; Friedman AH; Bigner DD
Cancer; 2005 Oct; 104(8):1693-9. PubMed ID: 16116609
[TBL] [Abstract][Full Text] [Related]
16. Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study.
Rodriguez FJ; Scheithauer BW; Jenkins R; Burger PC; Rudzinskiy P; Vlodavsky E; Schooley A; Landolfi J
Am J Surg Pathol; 2007 Mar; 31(3):351-62. PubMed ID: 17325476
[TBL] [Abstract][Full Text] [Related]
17. Caveolin-1 expression in diffuse gliomas: correlation with the proliferation index, epidermal growth factor receptor, p53, and 1p/19q status.
Barresi V; Buttarelli FR; Vitarelli EE; Arcella A; Antonelli M; Giangaspero F
Hum Pathol; 2009 Dec; 40(12):1738-46. PubMed ID: 19716156
[TBL] [Abstract][Full Text] [Related]
18. Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas.
Senetta R; Trevisan E; Rudà R; Maldi E; Molinaro L; Lefranc F; Chiusa L; Lanotte M; Soffietti R; Cassoni P
J Neuropathol Exp Neurol; 2009 Apr; 68(4):425-31. PubMed ID: 19287309
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of malignant features in oligodendroglial tumors.
Saito A; Nakazato Y
Clin Neuropathol; 1999; 18(2):61-73. PubMed ID: 10192700
[TBL] [Abstract][Full Text] [Related]
20. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; du Plessis DG; Warnke PC
Neurology; 2006 Jun; 66(11):1661-7. PubMed ID: 16769937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
